✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- Three molecules, three receptor architectures. Semaglutide activates GLP-1 only. Tirzepatide activates GLP-1 + GIP. Retatrutide activates GLP-1 + GIP + glucagon.
- Effect-size hierarchy tracks receptor count. Semaglutide STEP-1: -14.9% at 68 wk. Tirzepatide SURMOUNT-1: -22.5% at 72 wk. Retatrutide Phase 2: -24.2% at 48 wk.
- Regulatory status splits the three. Semaglutide (Ozempic/Wegovy/Rybelsus) is FDA-approved. Tirzepatide (Mounjaro/Zepbound) is FDA-approved. Retatrutide is in Phase 3 with no approved product yet.
- The glucagon arm in retatrutide adds direct hepatic energy expenditure on top of appetite suppression — the mechanistic explanation for the depth-of-effect advantage.
- This guide compares the three on mechanism, trial data, side-effect profile, dosing, and research-protocol applicability.
Retatrutide vs Tirzepatide vs Semaglutide: Triple Agonist vs Dual Agonist vs GLP-1 Monoagonist Compared
These three molecules define the modern incretin-pharmacology obesity-drug class. Each represents an evolutionary step in the receptor-architecture story — semaglutide established the GLP-1 monoagonist class, tirzepatide added GIP, retatrutide added glucagon. The depth-of-effect-size readouts in published trials track the receptor-count progression closely. This guide compares the three across every dimension that matters for research-protocol design: mechanism, trial readouts, side-effect profile, dosing, and where each fits in current research.
Quick verdict
- Maximum effect size: Retatrutide (-24.2%). Triple agonist; Phase 3 in progress.
- Most clinically validated: Tirzepatide (Mounjaro/Zepbound, FDA-approved 2022/2023; SURMOUNT-1 -22.5%).
- Class-defining reference: Semaglutide (Ozempic/Wegovy, FDA-approved 2017/2021; STEP-1 -14.9%).
- For research-protocol comparator design: Use Semaglutide as the GLP-1 baseline arm, Tirzepatide as the dual-agonist arm, Retatrutide as the triple-agonist arm.
Mechanism: how three receptors produce three effect sizes
The incretin family of gut hormones — GLP-1, GIP, glucagon — coordinates postprandial glucose handling, satiety signalling, and (for glucagon specifically) hepatic energy mobilisation. The three molecules above each activate one or more of these receptors.
GLP-1 (glucagon-like peptide-1) drives the appetite-suppression and slowed-gastric-emptying effects that dominate the incretin class’s weight-loss mechanism. Hypothalamic GLP-1 receptors mediate the satiety signal; peripheral GLP-1 receptors in the GI tract slow gastric emptying. Semaglutide is a GLP-1 monoagonist — its entire mechanism runs through this receptor.
GIP (glucose-dependent insulinotropic polypeptide) adds an enteroinsular axis arm. The published mechanism literature shows GIP activation in combination with GLP-1 deepens the appetite-suppression effect and may attenuate the GI-side-effect profile relative to GLP-1 monoagonism. Tirzepatide adds this arm; the SURMOUNT-1 readout (-22.5%) is substantially deeper than semaglutide’s STEP-1 (-14.9%) at comparable time points.
Glucagon is the differentiator that makes retatrutide a triple agonist. Glucagon receptor activation increases hepatic glucose output and direct hepatic energy expenditure — it raises the basal metabolic rate, working through a fundamentally different mechanism than the appetite-suppression arm. Retatrutide’s Phase 2 (-24.2%) deepens further than tirzepatide and also produces favourable hepatic-lipid readouts (MASH/fatty-liver endpoints).
Trial data side by side
| Trial | Molecule | Mean weight loss | Duration | Top dose |
|---|---|---|---|---|
| STEP-1 | Semaglutide | -14.9% | 68 wk | 2.4 mg weekly |
| SURMOUNT-1 | Tirzepatide | -22.5% | 72 wk | 15 mg weekly |
| Phase 2 (NEJM 2023) | Retatrutide | -24.2% | 48 wk | 12 mg weekly |
Caveat on direct comparison: STEP-1 ran 68 weeks; SURMOUNT-1 ran 72 weeks; retatrutide’s Phase 2 ran 48 weeks. Retatrutide’s effect size at 48 weeks already exceeds tirzepatide’s at 72 weeks, suggesting an even larger 72-week readout is likely — but the matched comparison only exists at 48 weeks. The TRIUMPH Phase 3 program will provide the full timeframe-matched data.
Comparison table
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor arms | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Comparator drug status | Ozempic/Wegovy/Rybelsus (FDA 2017/2021/2019) | Mounjaro/Zepbound (FDA 2022/2023) | Phase 3 (TRIUMPH) |
| Half-life | ~7 days | ~5 days | ~6 days |
| Dosing | Weekly SC; 0.25 to 2.4 mg titration | Weekly SC; 2.5 to 15 mg titration | Weekly SC; titrate to 12 mg |
| Hepatic / MASH effect | Modest | Modest to substantial | Substantial (glucagon arm) |
| Cardiovascular outcomes data | SELECT trial: -20% MACE | SURPASS-CVOT in progress | Not yet published |
Side-effect profile across the three
The class-level side-effect signature — nausea, delayed gastric emptying, occasional vomiting, gallstone risk with rapid weight loss, rare pancreatitis signal — appears across all three molecules. The notable differences:
- Semaglutide: GI side effects are the most prominent within this class because GLP-1 monoagonism produces the strongest direct gastric-emptying effect. Most subjects tolerate after 4-6 week titration.
- Tirzepatide: Published research suggests adding GIP attenuates the GI side-effect profile somewhat relative to matched-dose GLP-1 monoagonism — possibly because GIP has effects on glucagon and other arms that buffer the pure GLP-1-driven nausea pathway.
- Retatrutide: The glucagon arm introduces additional considerations including increased hepatic glucose output (which is counterbalanced by GLP-1’s insulin-secretion-amplifying effect) and modest blood-pressure effects in some published research. The overall tolerability profile in Phase 2 was comparable to tirzepatide at matched effect sizes.
Which to pick (research-protocol logic)
- Baseline / class-reference research: Semaglutide. The molecule that defined the modern obesity-pharma class; the comparator everything else is benchmarked against.
- Regulatory-precedent dual-agonist research: Tirzepatide. Has FDA-approved comparator drugs for both diabetes and obesity indications.
- Maximum-effect-size research / triple-agonist mechanism: Retatrutide. Phase 3 in progress; the molecule defining the upper bound of incretin-class effect size.
- Three-arm research design: Use all three in the same protocol to measure receptor-arm contribution explicitly.
Safety and regulatory status
The compounds on this page are sold for in-vitro laboratory research and analytical reference use only. Where comparator drugs are FDA-approved (Ozempic/Wegovy/Rybelsus for semaglutide; Mounjaro/Zepbound for tirzepatide), those approvals refer to the finished pharmaceutical product, not the research-grade lyophilized peptide. Retatrutide has no approved comparator drug. Class-level safety considerations include GI side effects, gallstone formation with rapid weight loss, rare pancreatitis signal, hypoglycaemia in subjects with intact glucose counter-regulation, and a theoretical thyroid C-cell tumour signal (boxed warning on GLP-1 drug labels; preclinical only). None of this is medical advice.
FAQ
Why does adding receptors deepen the effect?
Because the three receptors drive partially independent mechanisms. GLP-1 dominates appetite suppression and gastric emptying. GIP adds enteroinsular-axis effects that deepen satiety and may attenuate side effects. Glucagon adds direct hepatic energy expenditure. Activating multiple non-overlapping pathways produces additive (or near-additive) effect sizes.
Will retatrutide replace tirzepatide and semaglutide in clinical use?
That’s a clinical-decision question outside research scope, but the framing is too binary. Each molecule’s positioning depends on effect size needed, side-effect tolerability for the individual, cost / insurance access for the finished pharmaceutical product, and the specific indication. Phase 3 readouts and post-approval real-world data over the next 2-3 years will clarify the comparative positioning.
Is the dose ladder the same across all three?
No. Semaglutide titrates from 0.25 mg to 2.4 mg weekly over ~16 weeks; tirzepatide titrates from 2.5 mg to 15 mg weekly; retatrutide titrates to 12 mg weekly. Dose comparisons across molecules need to account for receptor-arm activation patterns — “milligrams” is not a meaningful equivalence unit because the molecules have different receptor profiles.
What about cardiovascular outcomes data?
Semaglutide has the most mature CV outcomes data — the SELECT trial showed -20% MACE in adults with obesity and established cardiovascular disease. Tirzepatide has SURPASS-CVOT in progress. Retatrutide CV outcomes data is not yet published.
How do these molecules differ in cost and supply (research-grade)?
Pricing on the research-grade catalogue tracks development stage and supply availability. Semaglutide and tirzepatide have wider supply networks. Retatrutide ships at higher per-mg pricing reflecting earlier development stage. See: Retatrutide buying guide.
Can I stack any of these together?
Within the GLP-1/GIP/glucagon receptor family, the answer is generally no — stacking semaglutide with tirzepatide or retatrutide is mechanistically redundant (overlapping GLP-1 arms) and creates dose-uncertainty for the individual molecules. The clinical practice is to use one incretin compound at appropriate dose. The exception is amylin stacking: cagrilintide (an amylin analogue, distinct mechanism) is the established stack partner for semaglutide (the CagriSema combination). See: Cagrilintide vs Semaglutide.
What’s the storage protocol?
Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw. See: Reconstitution calculator and BAC water guide.
Bottom line
The three molecules form a clean effect-size progression that tracks receptor-arm count: semaglutide (GLP-1) at -14.9%, tirzepatide (GLP-1 + GIP) at -22.5%, retatrutide (GLP-1 + GIP + glucagon) at -24.2%. Semaglutide and tirzepatide are clinically validated with FDA-approved comparator drugs; retatrutide is Phase 3 with the deepest published Phase 2 readout. For research-protocol design, the three define the modern incretin-class mechanism space. Within the broader peptide catalogue, see also the Best peptides for fat loss hub for the wider context.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.